"studyEstimands","name","id","studyInvestigationalInterventions","bcCategories","uuid:ID","label","studyDesignRationale","description","documentVersion"
"[]","Study Design 1","StudyDesign_1","[]","[]","2addb524-5570-4b06-a663-5ae2c460c077","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study",""
